TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3322472

Group type: EXPERIMENTAL
Intervention: Peroxide disinfection of drainage bags
Number of subjects: 0

Group type: COMPARATOR
Intervention: No disinfection technique (Control)
Number of subjects: 0
Study: 30941550

Group type: EXPERIMENTAL
Intervention: Laparoscopic group (LG)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Hybrid group (HG)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 193
Study: 30579334

Group type: EXPERIMENTAL
Intervention: Forced-air skin surface warming for 20 minutes before spinal anesthesia (pre-warming group, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Passive insulation (control group, n=25)
Number of subjects: 50
Study: 27492064

Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic regimen
Number of subjects: 77

Group type: COMPARATOR
Intervention: 5-day antibiotic regimen
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 77
Study: 26280590

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24345687

Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Transmission of body weight (BW)
Number of subjects: 20
Study: 20887606

Group type: EXPERIMENTAL
Intervention: Partnership in Coping during a 3‐month clinical intervention period
Number of subjects: 56

Group type: COMPARATOR
Intervention: Medical treatment (Control)
Number of subjects: 56
Study: 18773729

Group type: EXPERIMENTAL
Intervention: Inversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Independent manipulation of hue and luminance
Number of subjects: 0
Study: 17061019

Group type: EXPERIMENTAL
Intervention: iv arginine (ARG, 0.5 g/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral protein load (PRO, 50 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: iv lipid‐heparin infusion (Li He, Intralipid 10% 250 ml)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral fat load (OIL, soy oil 40 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral glucose load (OGL, 100 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: oral fructose load (OFL, 100 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: iv saline (SAL, 3 ml)
Number of subjects: 6

Group type: COMPARATOR
Intervention: oral water load (WL, 200 ml)
Number of subjects: 6
Study: 12925043

Group type: COMPARATOR
Intervention: 50-mg day-1 dose of naltrexone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 50-mg day-1 dose of methadone
Number of subjects: 204

Group type: COMPARATOR
Intervention: 5-mg day-1 dose of buprenorphine
Number of subjects: 204
Study: 11029729

Group type: EXPERIMENTAL
Intervention: Fixed lingual arch treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (matched individuals)
Number of subjects: 23
Study: 9060545

Group type: EXPERIMENTAL
Intervention: IL-2 plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-2 plus rhuTNFR:Fc
Number of subjects: 20
Study: 8370294

Group type: EXPERIMENTAL
Intervention: Dobutamine (10 micrograms/kg/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood transfusion (800 mL of packed red blood cells in 90 mins)
Number of subjects: 16
Study: 3720755

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention programme including antihypertensive treatment, dietary advice, and smoking cessation advice applied for 10 years.
Number of subjects: 10004

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 10004
Study: 30115110

Group type: EXPERIMENTAL
Intervention: Transitional care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27671517

Group type: EXPERIMENTAL
Intervention: Transurethral resection (TUR) + photodynamic therapy (PDT) with alasens
Number of subjects: 45
Study: 23591944

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dynamic Stretching (DS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control Condition (No Stretching)
Number of subjects: 47
Study: 22224756

Group type: EXPERIMENTAL
Intervention: Music therapy (MT) and standard care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 60
Study: 20165833

Group type: EXPERIMENTAL
Intervention: Pelvicol graft
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional anterior repair
Number of subjects: 61
Study: 18755762

Group type: EXPERIMENTAL
Intervention: Structured care (minimum of one hour of care by a nurse or midwife trained in structured care)
Number of subjects: 5002

Group type: COMPARATOR
Intervention: Usual care (usual nursing or midwifery care)
Number of subjects: 5002

Group type: EXPERIMENTAL
Intervention: Structured care
Number of subjects: 5002
Study: 15966083

Group type: EXPERIMENTAL
Intervention: End-to-end (ETE) distal anastomosis
Number of subjects: 274

Group type: COMPARATOR
Intervention: End-to-side (ETS) distal anastomosis
Number of subjects: 274
Study: 12762176

Group type: EXPERIMENTAL
Intervention: Midazolam (single intravenous dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study: 9789586

Group type: EXPERIMENTAL
Intervention: EA + drug
Number of subjects: 42

Group type: COMPARATOR
Intervention: Drug
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MCAO + EA
Number of subjects: 42

Group type: COMPARATOR
Intervention: MCAO
Number of subjects: 42
Study: 8998394

Group type: EXPERIMENTAL
Intervention: Clozapine (n = 31)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Haloperidol (n = 11)
Number of subjects: 81
Study: 3230148

Group type: EXPERIMENTAL
Intervention: IV fructose‐1,6‐diphosphate (FDP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 10
Study: 29663958

Group type: EXPERIMENTAL
Intervention: SMS messaging for TB-related communications
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Voice calls for TB-related communications
Number of subjects: 348
Study: 29131079

Group type: EXPERIMENTAL
Intervention: Pain during myocardial infarction (MI)
Number of subjects: 140
Study: 26333890

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acid supplementation (four 1000-mg supplements daily containing eicosapentaenoic acid 1200 mg plus docosahexaenoic acid 800 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (four 1000-mg paraffin oil placebo capsules daily)
Number of subjects: 51
Study: 23296436

Group type: EXPERIMENTAL
Intervention: ePROfile discussed during consultation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control period (ePROfile not discussed)
Number of subjects: 176
Study: 20868642

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 338

Group type: COMPARATOR
Intervention: Both dosages
Number of subjects: 338
Study: 19186973

Group type: EXPERIMENTAL
Intervention: AS-G gel (ascorbic acid 2-glucoside) applied for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo gel applied for 12 weeks
Number of subjects: 73
Study: 17991923

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) as the primary endpoint in symptom management trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis and interpretation of PROs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methodologic aspects of design, analysis, and interpretation of symptom management trials
Number of subjects: 0
Study: 15557828

Group type: EXPERIMENTAL
Intervention: 10 mg dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11746299

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Waiting-list (WL) control group
Number of subjects: 94
Study: 9644707

Group type: EXPERIMENTAL
Intervention: i.v. administration sets changed every 48 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: i.v. administration sets changed every 24 hours
Number of subjects: 50
Study: 7936368

Group type: EXPERIMENTAL
Intervention: Saline enriched water (400 ml at 33 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oligomineral water (400 ml at 33 degrees C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Saline enriched water (400 ml at 18 degrees C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oligomineral water (400 ml at 18 degrees C)
Number of subjects: 24
Study: 3914998

Group type: EXPERIMENTAL
Intervention: 1 cc of 1% lidocaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 31696836

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily + LiESWT (2400 shockwaves)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Tadalafil 5 mg once daily alone
Number of subjects: 78
Study: 30078935

Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 0
Study: 27759486

Group type: EXPERIMENTAL
Intervention: Compaction technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Broaching technique
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study: 25173606

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - rosiglitazone
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - pioglitazone
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - overall
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - cumulative duration
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - lumbar spine BMD
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - femoral neck BMD
Number of subjects: 24544

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (TZDs) - hip BMD
Number of subjects: 24544
Study: 22994170

Group type: EXPERIMENTAL
Intervention: 10 Forever Free for Baby and Me (FFB) relapse prevention booklets
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual care control (UCC) - 2 existing smoking cessation materials
Number of subjects: 504
Study: 20837847

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (20 mg) plus albuterol (oral dose daily for 2 years)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glatiramer acetate (20 mg) plus placebo (oral dose daily for 2 years)
Number of subjects: 44
Study: 18853554

Group type: EXPERIMENTAL
Intervention: Composite face task administered at seven orientations
Number of subjects: 0
Study: 17379119

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg . kg(‐1) IV
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (intralipid, one mL . kg(‐1))
Number of subjects: 32
Study: 15078749

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1070
Study: 10792152

Group type: COMPARATOR
Intervention: Tenoxicam (40 mg intravenously)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg intravenously) plus sublingual isosorbide dinitrate (5 mg)
Number of subjects: 50
Study: 9286943

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) therapy
Number of subjects: 1932

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1932
Study: 8472522

Group type: EXPERIMENTAL
Intervention: ST-679 (1200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paracetamol (1000 mg)
Number of subjects: 40
Study: 2871668

Group type: EXPERIMENTAL
Intervention: Polyene fatty acid therapy (linseed oil, fish, and fish oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiatherogenic oil diet
Number of subjects: 0
Study: 31132422

Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) supplementation (125 mg daily for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (125 mg of starch daily for 8 weeks)
Number of subjects: 60
Study: 27477786

Group type: EXPERIMENTAL
Intervention: Stabilized stannous fluoride (SnF2) dentifrice (0.454% SnF2 + 0.077% sodium fluoride; total F = 1450 ppm F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP)/arginine dentifrice (1.1% SMFP + 1.5% arginine; total F = 1450 ppm F)
Number of subjects: 0
Study: 25568079

Group type: EXPERIMENTAL
Intervention: Intraduodenal lipid (long‐chain triglyceride emulsion)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intraduodenal protein (whey hydrolysate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 13
Study: 22918546

Group type: EXPERIMENTAL
Intervention: Breast crawl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no breast crawl)
Number of subjects: 0
Study: 20728384

Group type: EXPERIMENTAL
Intervention: buprenorphine:naltrexone ratio 166:1
Number of subjects: 10

Group type: COMPARATOR
Intervention: buprenorphine only
Number of subjects: 10
Study: 19516117

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (1.25 mg) injection 1 week before surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: No bevacizumab injection (Control)
Number of subjects: 41
Study: 16984497

Group type: EXPERIMENTAL
Intervention: Rabeprazole, 20 mg b.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15558528

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (25 to 200 mg once daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11139906

Group type: EXPERIMENTAL
Intervention: Biventricular (BV) pacing
Number of subjects: 222

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 222
Study: 9381772

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (5 intraarticular injections, one injection per week for 5 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 18
Study: 8359970

Group type: EXPERIMENTAL
Intervention: Short-term dietary history interview
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Long-term dietary history interview
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Long-term dietary history interview in heavier drinkers (> or = 20 g alcohol per day)
Number of subjects: 1937

Group type: EXPERIMENTAL
Intervention: Separate nutrients
Number of subjects: 1937
Study: 2877681

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg kg‐1
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.8 mg kg‐1
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no antagonist)
Number of subjects: 59
Study: 30916447

Group type: EXPERIMENTAL
Intervention: Large Bedside Entertainment and Relaxation Theater (BERT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Tablet screen
Number of subjects: 52
Study: 28799458

Group type: EXPERIMENTAL
Intervention: Pedometer-based physical activity program (12 weeks, daily 30-minute walks, individualized daily step targets)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 37
Study: 26679695

Group type: EXPERIMENTAL
Intervention: 0.45 g nitrate (NIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inert placebo (PLA)
Number of subjects: 20
Study: 24674307

Group type: EXPERIMENTAL
Intervention: Surveillance testing and patient complaints
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: False positive events
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: True cancer recurrences
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Testing and healthcare consultations
Number of subjects: 110
Study: 21325335

Group type: EXPERIMENTAL
Intervention: Reverse pull headgear (RPHG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: RPHG
Number of subjects: 22
Study: 20955582

Group type: EXPERIMENTAL
Intervention: Early assisted discharge intervention (discharged on the fourth day of admission and treated at home)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual inpatient hospital care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early assisted discharge intervention
Number of subjects: 0
Study: 19017042

Group type: EXPERIMENTAL
Intervention: 4% niacinamide cosmetic applied for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control cosmetic without niacinamide
Number of subjects: 30
Study: 16082640

Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12501045

Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg intravenously every 6 hours starting in the recovery room
Number of subjects: 112

Group type: COMPARATOR
Intervention: Saline solution administered every 6 hours starting in the recovery room
Number of subjects: 112
Study: 9578010

Group type: EXPERIMENTAL
Intervention: 6 mg/day TGB
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 36 mg/day TGB
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: TGB monotherapy
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-dose TGB (not attaining monotherapy)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Patients not attaining TGB monotherapy
Number of subjects: 123
Study: 7636894

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg and 10 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg or 50 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both Amlodipine and Hydrochlorothiazide
Number of subjects: 20
Study: 2526172

Group type: EXPERIMENTAL
Intervention: Raclopride 0.1 to 16 mg
Number of subjects: 8
Study: 900460

Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 1/2 hour (dosage=1/4 MAC hour)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 1 MAC hour (dosage=1 MAC hour)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Enflurane 1/2 MAC for 2 MAC hours (dosage=2 MAC hours)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group receiving halothane
Number of subjects: 17
Study: 31541606

Group type: EXPERIMENTAL
Intervention: Usual home care (UHC) plus a 30‐day nurse practitioner transitional care program
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Usual home care (UHC) plus nurse practitioner plus a 60‐day health coach program
Number of subjects: 495

Group type: COMPARATOR
Intervention: Usual home care (UHC)
Number of subjects: 495
Study: 30542961

Group type: EXPERIMENTAL
Intervention: Parenting style (especially monitoring)
Number of subjects: 6391

Group type: EXPERIMENTAL
Intervention: Occasional alcohol use by parents
Number of subjects: 6391

Group type: EXPERIMENTAL
Intervention: Maternal episodes of drunkenness
Number of subjects: 6391
Study: 27476828

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intermediate cervical block
Number of subjects: 86

Group type: COMPARATOR
Intervention: Superficial cervical block
Number of subjects: 86
Study: 26093161

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg bid
Number of subjects: 4221

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid
Number of subjects: 4221

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4221
Study: 23493756

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 21807323

Group type: EXPERIMENTAL
Intervention: 50 IU/kg/wk Epoetin beta
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no Epoetin beta)
Number of subjects: 54
Study: 19958585

Group type: EXPERIMENTAL
Intervention: Microsphere formulation of azithromycin with ethyl cellulose
Number of subjects: 0
Study: 16444650

Group type: EXPERIMENTAL
Intervention: Nasal spray
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual irrigation
Number of subjects: 50
Study: 14967278

Group type: EXPERIMENTAL
Intervention: Standard Hansatome microkeratome head
Number of subjects: 93

Group type: COMPARATOR
Intervention: Zero-compression Hansatome microkeratome head
Number of subjects: 93
Study: 11777261

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 6 weeks (Group AI‐6)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Amorolfine 5% nail lacquer once weekly for 24 weeks and 200 mg itraconazole once daily for 12 weeks (Group AI‐12)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Itraconazole monotherapy for 12 weeks (Group I‐12)
Number of subjects: 131
Study: 9510275

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheters (PAC) for perioperative monitoring and hemodynamic optimization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheters (PAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (intravenous hydration and perioperative monitoring without PACs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PAC patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: PAC patients and control group
Number of subjects: 120
Study: 7801337

Group type: EXPERIMENTAL
Intervention: Aggressive treatment of the overstimulated autonomic nervous system
Number of subjects: 0
Study: 3230152

Group type: EXPERIMENTAL
Intervention: CGS 16617 administered after food
Number of subjects: 12

Group type: COMPARATOR
Intervention: CGS 16617 administered in fasted state
Number of subjects: 12
Study: 30782930

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 150

Group type: COMPARATOR
Intervention: ACE inhibitor/angiotensin receptor blocker-based regimen
Number of subjects: 150
Study: 29608229

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1200 Hz stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3030 Hz stimulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5882 Hz stimulation
Number of subjects: 24
Study: 27215274

Group type: EXPERIMENTAL
Intervention: Andrographis paniculata (A. paniculata) 170 mg dried extract tablet b.i.d. p.o.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24977996

Group type: EXPERIMENTAL
Intervention: 2% lidocaine (L)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 21128991

Group type: EXPERIMENTAL
Intervention: 3TC/ZDV (150 mg/300 mg) followed by BILR 355/r (150 mg/100 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: BILR 355/r (150 mg/100 mg)
Number of subjects: 51